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Abstract. Background: Induction schedules in acute myeloid leukemia (AML) are based on 
combinations of cytarabine and anthracyclines. The choice of the anthracycline employed has 
been widely studied in multiple clinical trials showing similar complete remission rates. 
Materials and Methods: Using an ex vivo test we have analyzed if a subset of AML patients may 
respond differently to cytarabine combined with idarubicin, daunorubicin or mitoxantrone.  
Bone marrow (BM) samples of 198 AML patients were incubated for 48 hours in 96 well plates, 
each well containing different drugs or drug combinations at different concentrations. Ex vivo 
drug sensitivity analysis was made using the PharmaFlow platform maintaining the BM 
microenvironment. Drug response was evaluated as depletion of AML blast cells in each well 
after incubation. Annexin V-FITC was used to quantify the ability of the drugs to induce 
apoptosis, and pharmacological responses were calculated using pharmacokinetic population 
models.  
Results: Similar dose-respond graphs were generated for the three anthracyclines, with a slight 
decrease in EC50 with idarubicin (p=1.462E-06), whereas the interpatient variability of either 
drug was large. To identify those cases of selective sensitivity to anthracyclines, potency was 
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compared, in terms of area under the curve. Differences in anthracycline monotherapy potency 
greater than 30% from 3 pairwise comparisons were identified in 28.3% of samples. 
Furthermore, different sensitivity was detected in 8.2% of patients comparing combinations of 
cytarabine and anthracyclines.  
Discussion: A third of the patients could benefit from the use of this test in the first line induction 
therapy selection, although it should be confirmed in a clinical trial specifically designed. 
 
Keywords: Anthracycline; ex-vivo test; Idarubicin; Daunorubicin; Mitoxantrone; Acute myeloid leukemia; Personalized 
medicine. 
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Introduction. Induction 1st line schedules in de novo 
acute myeloid leukemia (AML) are based in a 
combination of an anthracycline with cytarabine (CYT) 
(3+7 schedule), obtaining complete remission (CR) 
rates of 70-80% after 1-2 cycles.1,2 Daunorubicin 
(DNR), idarubicin (IDA), mitoxantrone (MIT, an 
anthracenedione), and less frequently other 
anthracyclines have been employed in these schemes. 
The choice of the anthracycline employed has been 
widely studied in several randomized clinical trials 
(RCT),3-22 showing similar CR rates, with some 
exceptions in which IDA reported higher CR than 
DNR,4,6-8,12 finding reproduced in a Cochrane meta-
analysis.23 
Different ex vivo tests have been employed to select 
the most effective drug combination from the 
individualized sensitivity and resistance assays, but 
none of them have been recommended in clinical 
practice.24 We are developing a Precision Medicine 
(PM) test based on an actionable native environment 
method (PharmaFlow platform), which showed 
excellent correlations with clinical responses in AML, 
avoiding some limitations of other ex vivo assays.25  
The objective of this non-interventional study is to 
explore whether a significant percentage of patients 
AML samples may show different ex-vivo sensitivity 
to IDA vs DNR vs MIT combined with CYT. 
 
Patients and Methods. 
Patients and study design. A multicenter, prospective, 
non-interventional cohort study was carried out in 33 
Spanish institutions of the PETHEMA group. The 
inclusion period lasted five years (2012-2017), 
enrolling patients aged 18 years and older with newly 
diagnosed AML. Diagnosis and classification of AML 
were performed according to the World Health 
Classification (WHO) criteria.26 This study was 
approved by the Research Ethics Board of each 
participating institution and was conducted according 
to the Spanish law 14/2007 of biomedical research. 
Informed consent was provided to all patients. 
 
Vivia’s PharmaFlow PM Test.  
• Native environment whole bone marrow sample 
Ex vivo drug sensitivity analysis was made using the 
PharmaFlow platform (previously termed 
ExviTech®)25 maintaining the bone marrow (BM) 
microenvironment. A minimum BM sample volume 
between 1 and 2 ml was collected by aspiration at 
AML diagnosis, before starting induction 
chemotherapy, and was processed by an automated 
method in Vivia Biotech laboratories 24 hours after 
extraction. Samples were incubated for 48 hours in 96 
well plates, each well containing different drugs or 
drug combinations at different concentrations, enabling 
calculation of dose-response curves for every single 
drug (CYT, IDA, DNR, MIT) and combination used in 
treatments (CYT-IDA, CYT-DNR, CYT-MIT). The 
number of BM samples analyzed were 289 with IDA, 
333 with DNR and 274 with MIT. A more detailed 
description of the procedure has been published 
elsewhere.25 The concentrations assayed for each 
anthracycline were: 
- Concentrations for IDA (µM): > 0.0002 ; 0.001 ; 
0.002 ; 0.006 ; 0.01 ; 0.018 ; 0.02 ; 0.04 ; 0.05 ; 
0.055 ; 0.08 ; 0.13 ; 0.16 ; 0.2 ; 0.26 ; 0.4 ; 0.5 ; 
0.6 ; 1.5. 
- Concentrations for DNR (µM): > 0.001; 0.05 ; 
0.075 ; 0.093 ; 0.15 ; 0.18 ; 0.25 ; 0.3 ; 0.37 ; 
0.45 ; 0.75 ; 0.85 ; 1.25 ; 1.5 ; 2.7 ; 3. 
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- Concentrations for MIT (µM): > 0.001 ; 0.0016 ; 
0.008 ; 0.01 ; 0.04 ; 0.08 ; 0.2 ; 0.38 ; 0.6 ; 0.8 ; 1 ; 
2.33 ; 3.5 ; 7.  
• Modeling of ex vivo activity of CYT, IDA, DNR, 
MIT.  
Evaluation of drug response was done by counting 
the number of live pathological cells (LPC) remaining 
after incubation at increasing drug concentrations. 
Dying cells (apoptosis) were excluded using Annexin 
V-FITC. Pharmacological responses were estimated 
using pharmacodynamic (PD) population-based 
models27 which essentially perform the fitting of the 
dependent variable (natural log of LPC) in a non-linear 
mixed-effects model to derive typical population 
values (fixed effects) and the magnitude of inter-patient 
and residual variability (random effects). Model 
development was performed with the first-order 
conditional estimation method using interaction option 
with the software NONMEM (v7.2)28, according to the 
following equation: 
 
Where LPC0 parameter refers to the number of LPC 
after incubation in the absence of drug, Emax represents 
the maximum fractional decrease in LPC that the drug 
can elicit, EC50, is the drug concentration exerting half 
of Emax , and γ is the parameter governing the steepness 
of the LPC vs drug concentration (C) curve. Potency 
(EC50) and efficacy (Emax) are PD parameters that 
characterize the pharmacological response and are 
integrated into a single value corresponding to the 
measurement of the area under the dose-response curve 
(Area Under the Curve, AUC). 
For data presentation, the survival index was 
computed, with the number of LPC in control wells 
that were not exposed to any drugs being set as 100%. 
The number of live cells in each drug-treated well was 
compared with this control value, and the survival 
index for each drug at each concentration was 
determined as the percentage of LPC at every tested 
concentration. 
Interpatient variability (IPV) associated with all 
parameters was described using an exponential model 
of the components of variance. An additive error 
structure was used for the residual variability. 
Population PD models were built with BM samples 
from 227 patients that were incubated with IDA, 271 
with DNR, and 212 with MIT. Bayesian estimation 
methods were then used to retrieve individual patient 
parameters based on their available exposure-response 
measurements in conjunction with the PD population 
parameters. After several trials with different modeling 
strategies, we could conclude that optimal approach, in 
terms of correlation with clinical output, was achieved 
by forcing typical parameters to values obtained in a 
different model using a dataset from samples tested at 
72h. Therefore, the typical parameter value for the 
maximum fractional effect (Emax) was set to 1 for both 
drugs. For γ, the typical parameter value was calculated 
but limited to the range 0-3. IPV for both parameters 
could not be determined with this dataset.  
For interaction analysis, a Surface Interaction 
model29 was used to estimate the degree of synergy, 
referred as α parameter, between both drugs (R 
environment (v3.3.1) for statistical computing).30 In 
this analysis, a value equal to 0 is an additive effect, a 
value > 0 indicates a synergistic effect, and a value < 0 
reflects an antagonistic effect. 
 
Study endpoints. The primary end-point was the 
comparison between the selective sensitivities of the 
different anthracyclines individually using the AUCs in 
the dose-response curve. For the comparisons between 
the combinations of anthracyclines with CYT, we 
employed the volume under the surface (VUS) of the 
dose-response curves. Besides, the differences in either 
drug potency or synergism ex vivo were also calculated 




Patient Characteristics. Overall, 332 BM samples from 
patients with AML suspicion were received at the 
laboratory, from which 261 BM samples were 
completely monitored at the end of the study. Of them, 
63 (24%) were not evaluable because of the following 
protocol issues: 1) incorrect informed consent form (32 
patients), 2) no available case report form (23 patients), 
3) misdiagnosis (3 patients), and 4) other unknown 
reasons (5 patients). Overall, clinical data from 198 
patient’s samples (60%) were available at the end of 
this study. The main baseline characteristics of these 
patients are displayed in Table 1. In summary, the 
median age was 61 years (range, 19 to 91), all patients 
were newly diagnosed AML, and 37 patients (19%) 
were categorized as having high-risk cytogenetics. CR 
rate was obtained in 93 patients (47%), whereas 65 
patients obtained partial remission or were resistant to 
induction. 
 
Ex vivo PharmaFlow Test characterization of IDA, 
DNR and MIT models. Dose-response graphs were 
generated for the single drugs (IDA, DNR, and MIT) 
using PD models (Figure 1). Most of the observations 
were contained within the simulation-based 95% 
confidence intervals of the 5-95th population 
percentiles proving good predictability of the selected 
models. Pharmacological population parameters, as 
well as variability and error values, are shown in Table 
2.  
The average dose-responses of the three anthracyclines 
were similar, with a slight decrease in EC50 values with 
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Table 1. Baseline characteristics of the 198 analyzed patients.  
 Median Range 
Age (years) 61 19-91 
 n % 
18-29 7 3.5 
30-39 20 10.1 
40-49 31 15.7 
50-59 30 15.2 
>60 110 55.6 
Gender n % 
Male 113 57 
Female 85 43 
ECOG n % 
0 57 29 
1 73 37 
2 24 12 
3-4 8 4 
Unknown 36 18 
FAB subtype n % 
M0 14 7 
M1 46 23 
M2 44 22 
M4 32 16 
M5 27 14 
M6 2 1 
Unknown 33 17 
 Median Range 
WBC (count x 109/L) 18.65 0.6 - 270 
 n % 
0-10 74 37 
10-50 63 32 
>50 51 26 
Unknown 10 5 
Cytogenetic risk profilea n % 
Favorable 15 8 
Intermediate 111 56 
Adverse 37 19 
Unknown 35 18 
FLT3-ITD status n % 
Wild 119 60 
Mutant 22 11 
Unknown 57 29 
NPM1 status n % 
Wild type 92 46 
Mutant 50 25 
Unknown 56 28 
Response n % 
CR/CRi 93 47 
PR/resistance 65 33 
Unknown 40 20 
aBased on the risk groups described by Grimwade et al (2010). 
ECOG-PS: Eastern Cooperative Oncology Group performance 
status; FAB: French-American-British classification; FLT3-ITD: 
fms-like tyrosine kinase 3-internal tandem duplication; NPM1: 
Nucleophosmin 1; WBC: white blood cells; PR: partial remission. 
the results of the clinical trials.4,6-8,12 However, the 
interpatient variability of either drug is quite large 
(Table 2, Figure 1), which could explain why some 
patients could show very differential sensitivities to 
these three drugs. As an example, Figure 2 illustrates a 
patient sample that is resistant to IDA and DNR (right 
shifted dose-response curve) but sensitive to MIT (left 
shifted dose-response curve).  
To identify these cases of selective sensitivity to 
anthracyclines, we compared the potency, regarding 
AUC, between IDA vs. DNR, IDA vs. MIT, and DNR 
vs. MIT (Figure 3, Table 3). Most dots tend to line up, 
but red dots represent patient samples with a difference 
in potency between these drugs >30%. Red dots from 3 
pairwise comparisons identify 28.3% of patient 
samples with >30% different potency among IDA-
DNR-MIT (Figure 4).  
 
Ex vivo PharmaFlow Test characterization of CYT-
IDA, CYT-DNR, and CYT-MIT combinations and their 
synergism. The pairwise comparison of the 
combination treatments CYT-IDA, CYT-DNR, and 
CYT-MIT obtained differential sensitivity to these 
anthracyclines (red dots of Figure 5). In this case, the 
red dots represent patient samples with a difference in 
CYT + anthracyclines synergy differences >30%, and 
 
Table 2. Estimates of the ex vivo population pharmacodynamic 
parameters. Parameters typical and random (variability and residual 
error percentage) are shown together with the corresponding 
relative standard error calculated as the ratio between the standard 
error provided by NONMEM and the estimate. Estimates of inter-




Mitoxantrone Idarubicin Daunorubicin 
LPC0 (cells) 7443 ( 10.04 ) 8384 ( 14.18 ) 7926 ( 10.21 ) 
Emax (unitless) 1 ( - ) 1 ( - ) 1 ( - ) 
EC50 (μM) 0.329* ( 16.84 ) 0.07* ( 14.58 ) 0.458*( 12.08 ) 
γ (unitless) 0.77 ( - ) 1.04 ( - ) 1.13 ( - ) 
Residual Error 
(log(μM)) 




   
LPC0 86.4 ( 6.56 ) 107.3 ( 6.83 ) 92.9 ( 5.76 ) 
Emax N/D N/D N/D 
EC50 224.2 ( 6 ) 181.8 ( 5.46 ) 168.6 ( 4.6 ) 
γ N/D N/D N/D 
Residual Error 
83.1 ( 7.63 ) 107.4 ( 7.21 ) 97.4 ( 6.38 ) 
Emax: maximum fractional decrease in live pathological cells that 
the drug can elicit; EC50: drug concentration exerting half of Emax; 
LPC0: Starting live pathological cells in the absence of drug; N/D: 
not determined; γ: parameter governing the steepness of the LPC vs 
drug concentration curve. 
 * p value = 1.462E-06 
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Figure 1. Average and Individual Dose Responses ex vivo for 
AML Drugs. Dose-Response Analysis was Completed for 3 
Anthracyclines in Bone Marrow Samples From Patients With Acute 
Myeloid Leukemia; 227 with Idarubicin, 212 with Mitoxantrone 
and 271 with Daunorubicin. The Survival Index (y-Axis) Ranges 
From 100% to 0%, Displaying the Selective Acute Myeloid 
Leukemia Cell Depletion Calculated With Population Models. The 
Gray Lines Display Each Individual Response, With the Median 
Response Shown in yellow for Idarubicin, Panel (A); in blue for 
Mitoxantrone, Panel (B); and in red for Daunorubicin, Panel (C). 
 
 
Figure 2. Example of differential individual sensitivities to 
anthracyclines. Dotted lines represented individual response to each 
drug and cotinuous lines the median response to each drug. Panel 
(A) shows an example of a patient resistant to Idarubicin (right 
shifted dose response curve) but sensitive to Mitoxantrone (left 
shifted dose response curve). Panel (B) shows an example of a 
patient resistant to Idarubicin and Daunorubicin (right shifted dose 
response curve). Panel (C ) shows an example of a patient resistant 
to Daunorubicin (right shifted dose response curve) but sensitive to 
Mitoxantrone (left shifted dose response curve). 
Table 3. Differences in Area Under the Dose-Response Curve between anthracyclines.  
 AUC 
 Over30% Normal Total % 
DNR_IDA 15 102 117 12.82 
DNR_MIT 32 172 204 15.69 
IDA_MIT 17 100 117 14.53 
AUC: area under the curve; DNR: daunorubicin; IDA: idarubicin; MIT: mitoxantrone. 
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Table 4. Differences in Volume Under the Surface (VUS) between the combinations of cytarabine and different anthracyclines.  
 VUS 
 Over30% Normal Total % 
CYT+DNR_CYT+IDA 2 125 127 1.57 
CYT+MIT_CYT+IDA 6 81 87 6.90 
CYT+DNR_CYT+MIT 9 153 162 5.56 
CYT: cytarabine; DNR: daunorubicin; IDA: idarubicin; MIT: mitoxantrone; VUS: volume under the surface. 
 
 
Figure 3. Comparison of the potency between anthracyclines. 
Panels A-C represented the pairwise comparisons between Area 
Under (AUC) the Dose-Response Curve of the anthracyclines, with 
their bisectors, linear regression lines and R2 values. Red dots 
represent patient samples with a difference in potency between 
these drugs greater than 30%. Panel (A) comparison between AUCs 
of Idarubicin and Mitoxantrone; Panel (B) comparison between 
AUCs of Daunorubicin and Mitoxantrone; Panel (C) comparison 
between AUCs of Daunorubicin and Idarubicin. 
red dots from 3 pairwise comparisons identified an 
8.2% of patient samples (Figure 6, Table 4).  
Furthermore, the values for the alpha parameters of 
the interaction models of CYT-IDA, CYT-MIT, CYT-
DNR were 0.72, 0.59 and 0.25, indicating synergistic 
response in the ex vivo combination experiments. 
 
Discussion. The findings of this study show that 
PharmaFlow PM test seems able to identify a subset of 
AML patients who have a significantly different ex 
vivo pharmacological response to anthracycline drugs. 
We can hypothesize that if these selective 
anthracycline ex vivo responses were translated to in 
vivo responses, a fraction of this 28.3% subpopulation 
could benefit significantly from receiving a specific 
anthracycline-based on the ex vivo test sensitivity 
results. Furthermore, an 8.2% of patients showed a 
significant difference in the synergy between CYT and 
anthracyclines, in which the choice of the anthracycline 
could be crucial. 
The first line induction therapy recommended by 
ELN1 and NCCN2 clinical guidelines includes seven 
days of a standard dose of CYT plus three days of an 
anthracycline, especially IDA (12 mg/m2) or DNR (60-
90 mg/m2). The combination of CYT-MIT was not 
considered standard therapy, although it has been 
widely employed.  
The influence of the anthracycline´s selection in the 
efficacy of induction therapy was analyzed in some 
RCTs.3-22 The comparison between CYT-DNR and 
CYT-IDA has been studied in 13 different trials,3-15 but 
only five studies reported differences in CR rates in 
favor of CYT-IDA.4,6-8,12 A meta-analysis confirmed 
the superiority of CYT-IDA against CYT-DNR, 
obtaining higher overall survival (OS), disease-free 
survival (DFS), CR, lower relapse rate, although this 
scheme increased induction death and mucositis.23 
Regarding the employment of CYT-DNR or CYT-
MIT, a clinical trial reported similar CR, length of 
duration of CR, OS, and toxicity.16 No evidence of 
differences between CYT-IDA and CYT-MIT in CR, 
survival rates, and toxicity was observed in 6 
RCTs9,11,17-20 and one meta-analysis.23 Combinations of 
CYT-doxorubicin showed worse outcomes than CYT-
DNR21 and CYT-IDA.22 According to clinical trials, in 
our study the average dose-responses of IDA, DNR, 
and MIT were similar, with a slight decrease in EC50
 




Figure 4. Differences in Area Under the Dose-Response Curve between anthracyclines. A 28.3% of patients samples showed >30% different 
potency among Idarubicin-Daunorubicin-Mitoxantrone Area Under the Dose-Response Curve (AUC). 
 
with IDA, indicating a probable higher potency with 
IDA than DNR and MIT. However, the anthracycline 
dosage of induction protocols assumed a cumulative 
doses proportion of 4:1 for DNR: IDA and DNR: 
MIT,31 but these proportions are not based in well-
designed trials. In our cohort, according to this 
proportion and EC50 of DNR (0.458), the estimated 
EC50 of IDA and MIT was 0.115, a proportion 1.6 fold 
higher than IDA EC50 and three fold lower than MIT 
EC50 measured with ex vivo test.  
Other studies analyzed the role of different 
anthracyclines in the AML induction with CYT and a 
third component, but CR and survival rates were 
similar for DNR, MIT, and aclarubicin.32,33 Besides the 
selection of the anthracycline, the dose intensity is 
crucial in the therapy success. An RCT34 reported 
significant improvements in CR, OS and event-free 
survival (EFS) using DNR doses of 90 mg/m2 
compared to doses of 45 mg/m2. The response-oriented 
individualized induction therapy is another approach 
tested with IDA+CYT scheme without any advantage 
over the standard scheme.35 In addition, some specific 
AML characteristics could modify the anthracycline 
response, such as FLT3-ITD mutated patients which 
showed higher CR and survival with high-dose DNR 
compared to standard-dose DNR or IDA.36,37 These 
findings were reproduced in vitro in FLT3-ITD-
mutated cell lines.37 Unfortunately, we have not 
enough data to analyze the impact of this mutation in 
our cohort. 
Despite the previous experiences of ex vivo drug 
testing with limited sensitivity38-44, the PharmaFlow 
PM test aims to solve technical limitations including 
some novelties25:  
a) the use of whole BM sample, maintaining the 
native environment, which has been hypothesized that 
it can influence the emergence of resistance;45-48  
b) the increase of the accuracy obtained modeling 
ex vivo activity with PD population models in one 
single step;49  
c) the improvements in the measures performed by 
automated flow cytometry platform (PharmaFlow).  
The correlation between in vitro and in vivo therapy 
sensitivity of PharmaFlow PM test has been recently 
demonstrated in a cohort of 123 AML patients after 
induction therapy with CYT-IDA (most of these 
patients were also included in this study).50 This study 
achieved an 81% of overall accuracy in the correlations 
between test predictions and hematological response, 
identifying with success responders (CR/CR with 
incomplete recovery) in 93% of cases and non-
responders (partial remission/resistance) in 60% of 
cases. The present study generates a theoretical role of 
PM tests in individual anthracycline selection but does 
not provide enough data and critical analyses to allow 
to translate their use in the routine clinical practice. 
Regarding the synergism between anthracyclines 
and CYT, we observed a synergistic response with the 
three combinations, especially with CYT-IDA and 
CYT-MIT. In a previous study, we also reported a 
higher synergy with CYT-IDA and CYT-MIT 
combination and a trend to an additive effect with 
CYT-DAU.25 Curiously, a novel approach in AML 
therapy is the use of the liposomal formulation of CYT 
and DNR in a molar ratio concentration of 5:1, based
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Figure 5. Comparison of the potency between combinations of cytarabine and anthracyclines. Panels A-C represented the pairwise 
comparisons between Volume Under the Surface (VUS) of the combinations of cytarabine (CYT) with anthracyclines, with their bisectors, 
linear regression lines and R2 values. Red dots represent patient samples with a difference in potency between these drugs greater than 30%. 
Panel (A) comparison between VUS of Cytarabine + Mitoxantrone (CYT+MIT) and Cytarabine + Idarubicin (CYT+IDA); Panel (B) 
comparison between VUS of CYT+MIT and Cytarabine + Daunorubicin (CYT+DNR); Panel (C) comparison between VUS of CYT+DNR 
and CYT+IDA. 
 





Figure 6. Differences in Volume Under the Surface between combinations of cytarabine and different anthracyclines. An 8.2 % of patients 
samples obtained >30% of different sensitivity in Volume Under the Surface (VUS) of Cytarabine + Idarubicin (CYT+IDA), Cytarabine + 
Daunorubicin (CYT+DNR) and Cytarabine + Mitoxantrone (CYT+MIT). 
 
on a probable higher synergistic effect.51,52 
Furthermore, the pairwise comparisons between 
combinations of CYT-IDA, CYT-DNR, and CYT-MIT 
found in an 8.2% of patients synergy differences 
>30%, probably associated to the interpatient 
variability in drug sensibility observed in dose-
response graphs.  
Some limitations should be addressed in this study. 
First, this study analyzes the differences between ex 
vivo sensitivities to three different anthracyclines 
combined with CYT in BM samples of AML patients 
at diagnosis, but the correlation between ex vivo 
responses and clinical response was not analyzed. 
Second, although the incubation time was relatively 
short, additional transportation and processing time 
could lead, in several patients, to a non-affordable 
delay to start induction chemotherapy while receiving 
the test report. Third, associations of the different in 
vitro response of each anthracycline and specific 
characteristics of AML (age, WBC, cytogenetic risk, 
FLT3-ITD, and NPM1 status, etc.) were not analyzed. 
Finally, the findings reported are not yet validated in an 
independent cohort. 
 
Conclusions. The ex vivo PharmaFlow PM test 
obtained in a 28.3% of the BM samples analyzed 
overall differences in sensitivity to anthracyclines in 
monotherapy. This test could allow designing a trial to 
explore a personalized selection of anthracycline 
therapy in AML patients. A similar approach is being 
tested in a clinical trial by PETHEMA group in 
relapsed or refractory AML patients to select the 
salvage therapy based on the ex vivo sensitivity to 
conventional chemotherapy agents. The role an 
adequate selection in this subset of AML patients is 
critical because none of the salvage regimens53 has 
achieved outstanding CR rates, long-lasting remissions, 
and acceptable OS. 
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